Keywords
How to Cite
Abstract
The article highlights the updated recommendations of the European Society of Cardiology (2023) for the management of patients with diabetes and cardiovascular disease. Basic laboratory tests for diagnosing diabetes and prediabetes are given. A new scale for assessing cardiovascular risk in patients with diabetes − SCORE2-Diabetes − is discussed, which is used in patients without severe damage to target organs and symptoms of cardiovascular disease (CVD). The principles of hypoglycemic therapy are considered, focusing on drugs with proven prognostic effectiveness. The main drugs for the treatment of diabetes in CVD are SGLT2 inhibitors and GLP-1 RA. Algorithms for management of patients with diabetes and coronary heart disease, heart failure, chronic kidney disease and atrial fibrillation were analyzed.
References
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Aug 25:ehad192. doi: 10.1093/eurheartj/ehad192.
SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. European Heart Journal. 2023 July 21;44(28):2544-2556. h ttps://doi.org/10.1093/eurheartj/ehad260